Linezolid-induced hypoglycaemia in a patient with type 1 diabetes

Linezolid is a relatively novel oxazolidinone and its use is currently limited to secondary care in the UK. It is a reversible, non-selective monoamine oxidase inhibitor, but at the doses used for antibacterial therapy it does not exert an anti-depressive effect. It has a potentially serious side effect profile and is monitored intensively by the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency. Herein we report the rarely recognised complication of linezolid-induced hypoglycaemia in a patient with type 1 diabetes. Br J Diabetes Vasc Dis 2012;12:186-188.